Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings

Amita Gupta,1,10 Xin Sun,2 Sonya Krishnan,1 Mitch Matoga,1,9 Samuel Pierre,4,6 Katherine McIntire,1 Lucy Kooch,5 Sharlaa Faesen,6 Cissy Kityo,7 Sufia S. Dadabhai,1,8 Kogieulem Naidoo,8,10 Wadzanai P. Samaneka11, Javier R. Lama,12 Valdilea G. Veloso,13 Vidya Mave,1,14,15 Umesh Lalloo,15 Deborah Langat,16 Evelyn Hogg,16 Gregory P. Bisson,17 Johnstone Kumwenda,18 and Mina C. Hosseinipour,1,19 for the ACTG A5274/REMEMBER Study Team

1Johns Hopkins University, Baltimore, Maryland, USA, 2Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA, 3UNC Project, Lilongwe, Malawi, 4Les Centres GHESKIO, Port-au-Prince, Haiti, 5Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kericho, Kenya, 6Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa, 7Joint Clinical Research Centre, Kampala, Uganda, 8College of Medicine-Johns Hopkins Research Project, Blantyre, Malawi, 9Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa, 10Medical Research Council (MRC)-CAPRISA-HIV-TB Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa, 11University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe, 12Associação Civil Impacta Saúde e Educação, Lima, Peru, 13Instituto Nacional de Infectologia Evandro Chagas/FIOCRUZ, Rio de Janeiro, Brazil, 14Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India, 15Enhancing Care Foundation, Durban University of Technology, Durban, South Africa, 16Social & Scientific Systems, Inc., a DLH Holdings Company, Silver Spring, Maryland, USA, 17University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA, 18Department of Medicine, University of Malawi, Zomba, Malawi, and 19University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA

Background. People with human immunodeficiency virus (HIV) and advanced immunosuppression initiating antiretroviral therapy (ART) remain vulnerable to tuberculosis (TB) and early mortality. To improve early survival, isoniazid preventive therapy (IPT) or empiric TB treatment have been evaluated; however, their benefit on longer-term outcomes warrants investigation.

Methods. We present a 96-week preplanned secondary analysis among 850 ART-naive outpatients (≥13 years) enrolled in a multicountry, randomized trial of efavirenz-containing ART plus either 6-month IPT (n = 426) or empiric 4-drug TB treatment (n = 424). Exclusion criteria were CD4 count <50 cells/mm3 and no confirmed or probable TB. Death and incident TB were compared by strategy arm using the Kaplan-Meier method. The impact of self-reported adherence (calculated as the proportion of 100% adherence) was assessed using Cox-proportional hazards models.

Results. By 96 weeks, 85 deaths and 63 TB events occurred. Kaplan-Meier estimated mortality (10.1% vs 10.5%; P = .86) and time-to-death (P = .77) did not differ by arm. Empiric had higher TB risk (6.1% vs 2.7%; risk difference, −3.4% [95% confidence interval, −6.2% to −0.6%]; P = .02) and shorter time to TB (P = .02) than IPT. Tuberculosis medication adherence lowered the hazards of death by ≥23% (P < .0001) in empiric and ≥20% (P < .035) in IPT and incident TB by ≥17% (P ≤ .0324) only in IPT.

Conclusions. Empiric TB treatment offered no longer-term advantage over IPT in our population with advanced immunosuppression initiating ART. High IPT adherence significantly lowered death and TB incidence through 96 weeks, emphasizing the benefit of ART plus IPT initiation and completion, in persons with advanced HIV living in high TB-burden, resource-limited settings.

Keywords. isoniazid adherence; isoniazid preventive therapy; strategy trial; tuberculosis and HIV; tuberculosis prophylaxis.

Despite the scale-up of antiretroviral therapy (ART), tuberculosis (TB) remains the leading cause of death among people with human immunodeficiency virus (PWH) worldwide, accounting for 208 000 deaths in 2019 [1]. The risk of early mortality after initiating ART is particularly high in resource-limited settings and remains largely TB-related, with approximately 10% mortality during the first 3 months [2–6]. Reconstitution of the immune system with ART alone lowers the risk of TB infection by up to 65%, yet PWH remain especially vulnerable to TB in high-burden settings [7–9]. A CD4 count below 50 cells/mm3 confers the highest risk for early mortality [3, 5]. People with HIV with advanced immunosuppression continue to seek HIV care in various settings [10, 11], underscoring the critical need for TB control strategies beyond ART to improve survival in this highly vulnerable population and to achieve 2030 global

Received 16 March 2022; editorial decision 27 June 2022; accepted 01 July 2022; published online 3 July 2022

Correspondence: A. Gupta, MD, MHS, 1830 East Monument Street, #437, Baltimore, MD 21205 (agupta25@jhmi.edu)

Open Forum Infectious Diseases® © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

https://doi.org/10.1093/ofid/ofac325

IPT vs Empirc TB Treatment in Advanced HIV • OFID • 1
TB targets, namely, an 80% decrease in TB incidence and a 90% decrease in TB deaths compared with 2015 levels [1].

Isoniazid preventative therapy (IPT) in PWH is one such TB control strategy, with mounting evidence describing the independent and synergistic impact of IPT and ART to reduce the risk of TB and death [12–15]. World Health Organization guidelines now recommend ART initiation and at least 6 months of isoniazid prevention therapy (IPT) for all persons presenting for HIV care after excluding active TB, regardless of CD4 count or tuberculin skin test [16]. Overall, the population receiving TB prevention has expanded since 2015, growing from 1 million to 4.1 million in 2019, and PWH comprise the majority (3.5 million in 2019) [1]. However, coverage of PWH initiating ART with IPT varies from <1% to 89% in high TB- or HIV/TB-burden countries, with scale up predominantly localized to India (25%), United Republic of Tanzania (19%), South Africa (15%), Malawi (5%), and Zambia (5%) [1]. Despite the expanding body of evidence supporting IPT, concerns about unreliable TB diagnostics, poor adherence, and the potential for isoniazid resistance using a 1-drug regimen have contributed to persistently suboptimal global implementation and uptake [17–20].

Given the aforementioned concerns, providing preemptive 4-drug TB treatment at ART initiation has been investigated as an alternative strategy. Our group previously reported no early survival advantage of empiric 4-drug TB treatment over 6-month IPT in the 24-week analysis of the AIDS Clinical Trials Group (ACTG) A5274 REMEMBER (Reducing Early Mortality and Early Morbidity by Empirical Tuberculosis Regimens) trial (ClinicalTrials.gov Identifier NCT01380080) [21]. This randomized, open-label, phase IV strategy trial enrolled outpatients initiating ART with CD4 counts below 50 cells/mm² in 10 resource-limited, high TB-burden countries spanning sub-Saharan Africa, the Americas, and Asia. We now present the 96-week analysis of death and incident TB and include the important effect of adherence to TB medications through 24 weeks from this trial.

METHODS

The A5274 trial methods have been previously described in detail (Supplemental Methods) [21]. In brief, between 2011 and 2015, participants were recruited at 18 outpatient study sites in 10 resource-limited countries (Kenya, Malawi, South Africa, Uganda, Zambia, Zimbabwe, India, Brazil, Haiti, and Peru) characterized by both high TB incidence (>100 per 100 000 person-years) and early mortality after ART initiation (6-month mortality ≥5%). We enrolled ART-naive PWH aged ≥13 years who presented for ART initiation with CD4 counts <50 cells/mm² without confirmed or probable TB [21]. Tuberculosis screening was conducted for active TB using signs and symptoms (presence of cough lasting ≥2 weeks, any current fever >38°C, hemoptysis, night sweats within the past 2 weeks, unintentional weight loss >10% in past 30 days, or enlarged axillary or cervical lymph nodes) and locally available diagnostics, such as acid-fast bacilli smear, chest radiography, GeneXpert MTB/RIF assay (only available at 5 sites, n = 444), ultrasound, and mycobacterial culture. After June 2013, GeneXpert was required for initial TB screening and was conducted on stored baseline samples collected before this date (n = 398). Retrospectively, urine LAM testing was also performed on a subset of stored baseline samples (n = 566, n = 283 per arm) [22]. Exclusion criteria included exposure to single-dose nevirapine (past 2 years), TB treatment (past 96 weeks), IPT (past 48 weeks), or any household contact of multidrug-resistant TB. Inclusion criteria included liver function tests ≤2.5 times the upper limit of normal, creatinine clearance ≥30 mL/min, and Karnofsky score ≥30 at the time of study entry.

At entry, participants were randomized 1:1 to initiate ART plus either empiric 4-drug TB treatment or IPT; randomization was balanced by study site and stratified according to CD4 count (<25 vs ≥25 cells/mm³) and the presence of poor prognostic factors (none vs ≥1), namely, reportable hospitalization in past 30 days, body mass index <18.5 kg/m², or hemoglobin <8 g/dL. Follow-up visits were scheduled through 96 weeks after randomization (weeks 1, 2, 4, 8, 12, 16, 20, 24, 48, 60, 72, 84, and 96). The primary outcome was survival status at week 24, and a priori secondary analysis outcomes were survival status and incident TB at week 96.

Procedures

All participants received efavirenz-based ART (efavirenz/tenofovir/emtricitabine or efavirenz + locally available nucleoside reverse-transcriptase inhibitors). Empiric TB treatment consisted of weight-based, fixed-dose combination isoniazid/rifampin/ethambutol/pyrazinamide daily for 8 weeks followed by fixed-dose combination rifampin/isoniazid daily for 16 weeks. Isoniazid prevention therapy consisted of 300 mg isoniazid daily for 24 weeks. All participants received medications for self-administration, initiated treatment within 7 days of randomization, received pyridoxine while on isoniazid, and received local standard of care.

A sputum sample from each participant was stored at entry. At all visits, data were collected on signs and symptoms, ART modifications, concomitant medications, and clinical events, as defined by a standardized tool (ACTG Appendix 60) [21]. After enrollment in the study, participants in both groups who developed signs and symptoms were tested for TB using locally available diagnostics and treated accordingly. Self-reported adherence to TB medications and ART was recorded using the ACTG 4-day recall adherence questionnaire administered at week 1, 2, 4, 8, 12, 16, 20, and 24 [23]. Participants were transferred to locally provided care at week
Cochran-Mantel-Haenszel test was used to compare each end point probabilities between the treatment strategies after stratifying all those who were randomized. Participants who discontinued the study or had unknown survival status were censored at the last visit. The exact test was also used to compare the diagnosis of incident TB by 96 weeks among those who were retrospectively identified as having TB at baseline by GeneXpert or urine LAM. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC).

**RESULTS**

Of 1368 patients screened, 850 eligible participants were randomized to empiric treatment (*n* = 424) or IPT (*n* = 426) and were included in this analysis (Figure 1). The study population was 53% male, 90% were Black African or Black of African origin, the median age was 36 years (interquartile range [IQR], 30–42), and the median CD4 count was 18 cells/mm³ (IQR, 9–32) (Table 1). No individuals <18 years old were enrolled, and the participant’s gender identity information was not collected in this study.

**Primary Endpoints**

At week 96, 85 deaths, including 2 deaths occurring off study, were recorded (empiric *n* = 41; IPT *n* = 44), including 18 deaths after week 48 (empiric *n* = 11; IPT *n* = 7). Although mortality was higher in those with a CD4 cell count of less than 25 cells/mm³ and those with poor prognostic factors, the event rates were similar across groups for the stratification factors (Supplementary Table 1). Study groups did not differ by KM-estimated mortality (empiric 10.1% [95% CI, 7.5%–13.6%] vs IPT 10.5% [95% CI, 7.9%–13.9%]), yielding a risk difference of 0.4% (95% CI, −3.8% to 4.6%; *P* = .86) (Table 2), or time to death (log rank *P* = .77) (Figure 2A). These conclusions remained unchanged in the modified ITT analyses excluding participants who developed confirmed or probable TB (*n* = 36) or those who were retrospectively identified as MTB positive at entry via GeneXpert MTB/RIF and/or urine LAM assays (GeneXpert *n* = 6; urine LAM *n* = 28; total positive individuals *n* = 33) (Table 2). Five participants (3 in empiric and 2 in IPT) were retrospectively identified as MTB positive and died by week 96.

Overall, 58 participants were diagnosed with 63 TB events (confirmed, probable or clinical) by week 96 (Table 1). Of these, 51 (88%) participants developed TB by week 24; only 2 participants developed TB after week 48 (1 in each arm) (Figure 3A and B). By week 96, 36 participants developed confirmed or probable TB in empiric and 22 in IPT. There was no difference in the rate of incident TB across groups for the stratification factors (Supplementary Table 1). Among the participants who were retrospectively identified as MTB positive at baseline, there was no significant difference in the diagnosis of incident TB between the 2 arms by 96 weeks (Supplementary Table 2). Compared with IPT, empiric treatment had a higher probability of incident TB (6.1% [95% CI, 4.2%–8.9%] vs 2.7% [95% CI, 1.5%–4.9%]), with a risk difference of −3.4% (95% CI, −6.2% to −0.6%; *P* = .02) (Table 2), and a shorter time to TB diagnosis
Figure 1. CONSORT study flow diagram. ART, antiretroviral therapy; IPT, isoniazid preventive therapy; Lab, laboratory.

Table 1. Baseline Characteristics and Primary 96-Week Outcomes by TB Strategy

| Characteristic/Outcome | Overall (n = 850) | Empiric TB Treatment (n = 424) | Isoniazid Preventive Therapy (n = 426) |
|------------------------|------------------|-------------------------------|-----------------------------------|
| **Baseline characteristic** | | | |
| Median age, year (IQR) | 36 (30–42) | 36 (30–42) | 35 (30–42) |
| Male sex | 450 (53) | 224 (53) | 226 (53) |
| Race | | | |
| Black | 768 (90) | 380 (90) | 388 (91) |
| Indian | 30 (4) | 17 (4) | 13 (3) |
| Other | 52 (6) | 27 (6) | 25 (6) |
| Median CD4 count, cells/mm\(^3\) (IQR) | 18 (9–32) | 18 (9–11) | 19 (9–33) |
| Median HIV-1 RNA, log\(_{10}\) copies/mL (IQR) | 5.3 (4.9–5.7) | 5.4 (4.9–5.7) | 5.3 (4.9–5.7) |
| **Outcome at week 96** | | | |
| Death or unknown status | 85 (10.0) | 41 (9.7) | 44 (10.3) |
| Confirmed or probable TB | 36 (4.2) | 25 (5.9) | 11 (2.6) |
| Any TB\(^a\) | 58 (6.8) | 36 (8.5) | 22 (5.2) |
| Total TB events, n | 63 | 39 | 24 |
| Confirmed pulmonary | 20 | 14 | 6 |
| Confirmed extrapulmonary | 3 | 1 | 2 |
| Probable pulmonary | 8 | 5 | 3 |
| Probable extrapulmonary | 6 | 6 | 0 |
| Clinical pulmonary | 4 | 1 | 3 |
| Clinical extrapulmonary | 22 | 12 | 10 |

Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid; TB, tuberculosis.

*Data presented as n (%) or median (IQR) unless otherwise indicated.

*Any confirmed, probable, or clinical tuberculosis event as per AIDS Clinical Trials Group Appendix 60, including pulmonary and extrapulmonary (more than 1 event possible per participant). Confirmed TB is defined as microbiologically confirmed TB. Probable TB was defined as compatible clinical and/or radiological presentation (≥1 of the following: radiology compatible with TB; temperature >38°C; weight loss ≥10% of body weight; night sweats; known TB exposure; or absence of another diagnosis) and TB treatment initiated. Clinical TB was defined as TB cases where TB treatment was initiated.
to empiric TB treatment (solid line) compared with those who received isoniazid preventive therapy (IPT) dashed line). The monthly death rate decreased over the analysis period. Most deaths (93%) occurred by week 24, whereas time to incident TB was significantly more rapid among participants randomized to empiric TB treatment (solid line) compared with those who received isoniazid preventive therapy (IPT) dashed line).

**Table 2. Kaplan-Meier Estimates for Primary Outcomes With 95% CIs by TB Strategy Using Intention-to-Treat and Modified Intention-to-Treat Approaches**

| Approach                  | N  | Empiric | IPT | Risk Difference* | Empiric | IPT | Risk Difference* |
|---------------------------|----|---------|-----|------------------|---------|-----|------------------|
| Intention-to-treat        | 850| 10.1 (7.5–13.6) | 10.5 (7.9–13.9) | 0.4 (–3.8 to 4.6) | 6.1 (4.2–8.9) | 2.7 (1.5–4.9) | –3.4 (–6.2 to –0.6)* |
| Excluded MTB* at entry^a |    |         |     |                  |         |     |                  |
| GeneXpert MTB/RIF only   | 844| 10.0 (7.4–13.4) | 10.3 (7.8–13.7) | 0.4 (3.8–4.5) | 6.2 (4.2–9.0) | 2.7 (1.5–4.9) | –3.4 (–6.2 to –0.6)* |
| Urine LAM only           | 822| 10.4 (7.7–14.0) | 10.2 (7.6–13.6) | –0.2 (–4.5 to 4.0) | 5.7 (3.8–8.5) | 2.8 (1.5–4.9) | –2.9 (–5.8 to –0.1)* |
| GeneXpert MTB/RIF and/or Urine LAM | 817 | 10.2 (7.5–13.8) | 10.0 (7.5–13.4) | –0.2 (–4.4 to 4.1) | 5.7 (3.8–8.5) | 2.8 (1.5–5.0) | –2.9 (–5.8 to –0.1)* |
| Excluded incident TB^b   | 814| 9.0 (6.5–12.4) | 10.3 (7.7–13.7) | 1.3 (–2.8 to 5.5) | N/A      | N/A | N/A              |

Abbreviations: CI, confidence interval; IPT, isoniazid preventive therapy; LAM, lipoarabinomannan; MTB, Mycobacterium tuberculosis; N/A, not applicable; RIF, rifampicin; TB, tuberculosis. NOTE: Data presented as percentage (95% CI).

^aAbsolute risk difference (IPT–empiric).

^bExcluded participants who were retrospectively identified as MTB-positive using stored baseline samples tested via: GeneXpert only (n = 6); urine LAM only (n = 28); or by either assay (n = 33).

Denotes z-test, *P < .05.

Figure 2. Kaplan-Meier curves comparing time to death (A) and time to confirmed (Conf.) or probable (Prob.) tuberculosis (TB) (B) by TB treatment strategy. The Kaplan-Meier curves show that time to death did not significantly differ by TB strategy (A), whereas time to incident TB was significantly more rapid among participants randomized to empiric TB treatment (solid line) compared with those who received isoniazid preventive therapy (dashed line) (B).

Adherence to Tuberculosis and Antiretroviral Therapy Medications

At week 24, the mean self-reported adherence to IPT was 90.9% (standard deviation [SD] = 17.6%) versus 88.1% (SD = 19.6%) in empiric. Self-reported adherence to IPT was higher than adherence to empiric treatment (Wilcoxon rank-sum test P < .001), whereas adherence to ART did not differ by arm (Wilcoxon rank-sum test P = .73). Individuals who experienced death were more likely to have <100% cumulative adherence to both ART and TB medications across study visits (Supplementary Table 3). Higher adherence to TB medications through week 24 (10% increase in the proportion of 100% adherence) had a significant impact on mortality (empiric and IPT) and incident TB (IPT only) at each timepoint (24, 48, and 96 weeks), with at least 23% (P < .0001) and 20% (P ≤ .0035) lower hazards of death in empiric and IPT, respectively, and at least 17% (P ≤ .0324) lower hazards of confirmed or probable TB in IPT (Table 4). Isoniazid preventive therapy participants who survived at week 24 had a higher proportion of 100% IPT adherence at weeks 2, 8, 12, and 20 than those who...
died, and IPT participants with incident TB by 24 weeks had a lower proportion of 100% IPT adherence at weeks 1 and 8 than those without TB. Higher adherence to ART through week 24 reduced mortality and incident TB at each timepoint in both study groups, with at least 27% ($P < .0001$) and 22% ($P \leq .0048$) lower hazards of death and at least 15% ($P \leq .0329$) and 17% ($P \leq .0613$) lower hazards of TB in empiric treatment and IPT, respectively (Table 4).

**DISCUSSION**

This 96-week analysis of the multicountry A5274 REMEMBER trial indicates no longer-term survival benefit of empiric 4-drug TB treatment compared with 6-month IPT in our outpatient population initiating ART with advanced HIV without confirmed or probable TB. Compared with empiric treatment, IPT had a lower rate of confirmed or probable TB by 96 weeks, and adherence to IPT significantly reduced the hazards of early and longer-term mortality and incident TB through 96 weeks. These findings add to the growing evidence that empiric 4-drug TB treatment may not provide an advantage as a TB control strategy among individuals initiating ART with advanced HIV [24]. More importantly, our data clearly provide evidence supporting the implementation of ART plus 6-month IPT initiation and illustrate that adherence to and completion of IPT is essential to reduce TB and death in high TB-burden, resource-limited settings, even in the context of severe immunosuppression.

Our group previously reported no early survival benefit of empiric TB treatment and a higher rate of incident TB by 24 weeks compared with 6-month IPT [21]. We now report that these early outcomes are sustained through 96 weeks in our study population at high risk for TB and death. Two recent trials, TB Fast Track [25] and STATIS [26], have similarly reported no early mortality benefit of empiric TB treatment at 24 weeks among PWH with CD4 counts below 150 and 100 cells/mm$^3$, respectively. The STATIS trial also found no mortality benefit at 48 weeks [26]. Given the limitations of TB diagnostics in PWH, especially with advanced immunosuppression, empiric TB treatment would hypothetically improve survival by providing early TB treatment to patients with undetected active TB and prevent TB activation in those with latent TB infection [9]. However, we found that empiric treatment was not more effective than IPT in reducing longer-term mortality in our population, regardless of whether GeneXpert or urine LAM assays were used at TB screening. Furthermore, the early advantage of IPT to reduce TB risk was maintained through 96 weeks.

Although our results suggest at least a 2-year benefit of IPT, the actual duration of TB protection after initiation of ART plus IPT remains unclear in populations with very advanced HIV. Studies from Africa report TB risk gradually returns to baseline after completing 6-month IPT [27, 28]. A randomized controlled trial from Zambia found that the benefit of IPT (48% lower TB risk compared with placebo) lasted for at least 2.5 years and noted a diminished effect over the maximum follow-up of 7 years [29]. In contrast, recent long-term follow-up of the TEMPRANO (2×2 randomized controlled trial of IPT and ART from sub-Saharan Africa) and THRio (cluster-randomized phased treatment trial from Brazil) trials suggests that IPT may provide longer-term protection, specifically a 37% reduction in mortality at 6 years [30], with maintenance of
needed to understand the precise duration of TB protection from IPT, we identified only 1 additional TB event after week 48 and no TB-related deaths after 9 months, illustrating excellent protection from TB at least during 18 months after completing IPT.

Finally, our 96-week analysis indicates that adherence to IPT significantly improves early and longer-term outcomes, lowering the hazards of death and incident TB by at least 20% and 17%, respectively. To our knowledge, our study is among the first to examine such associations. Isoniazid preventive therapy completion rates ranging from 85% to 95% have been reported in study settings from high TB-burden areas [32–35], which are consistent with IPT adherence reported among our study population. Although these findings suggest high patient acceptability and feasibility of implementation, low IPT uptake and completion rates have been reported from real-world programmatic settings [36], emphasizing the need for national programs to overcome barriers and boost adherence. Potential strategies to improve IPT uptake and completion include integration of TB and HIV care [37], TB training for HIV providers [34], community-based delivery of IPT, video directly observed therapy via smartphone platforms [38, 39], use of adherence devices, such as medication event reminder monitor systems (MERMS), and interventions targeting groups with lower completion rates, such as younger patients and males [35]. In
addition, clinical trials have recently evaluated shorter 3-month and 1-month TB prevention regimens containing isoniazid and rifapentine, which have similar efficacy as 60- to 9-month IPT, but better completion and adherence rates [40], and may alleviate the fear of potential isoniazid resistance (ie, due to poor adherence to a 6-month, 1-drug regimen for prevention).

Our study has several limitations. Treatment assignment was not blinded, which could influence providers’ diagnosis and treatment decisions. Second, the length of follow-up limited our ability to fully assess and compare the lasting impact of IPT. In addition, we relied on self-reported adherence instead of using objective measures, such as urine isoniazid levels or pharmacokinetic measurements of rifampicin. Next, due to the low number of culture-confirmed TB cases, we were unable to assess drug resistance at the time of incident TB and could not address concerns about developing isoniazid resistance. Finally, it is unclear why adherence to empiric TB treatment was not also associated with a reduction in incident TB. With the observation that TB was more common in the empiric arm, particularly during the first 24 weeks, it is possible that there was an imbalance in the randomization that could have impacted our findings. A retrospective analysis of A5274 stored urine baseline samples revealed an increased incidence of positive urine LAM assays in the empiric arm compared with the IPT arm, which likely occurred by chance [22]. Finally, given that adherence was self-reported, it could be that the additional pill burden and side effects of the 4-drug regimen led to decreased rates of adherence in actuality. Despite these limitations, we were able to demonstrate the effectiveness of IPT to reduce longer-term mortality and TB risk compared with empiric TB treatment, including the impact of adherence, in a very high-risk study population with advanced HIV.

CONCLUSIONS

In conclusion, empiric 4-drug TB treatment offered no survival advantage over IPT and had a higher rate of incident TB in longer-term follow-up. Furthermore, a higher degree of IPT adherence substantially reduced the incidence of TB and death. These findings highlight not only the importance of TB preventive treatment (TPT) and concomitant ART initiation as an effective strategy to reduce TB and death in individuals with advanced HIV disease and no suspected TB, they also shed light on the necessity of adherence. As we transition to a new era of TPT, with an increasing variety of available treatment strategies, preference for shorter regimens to improve adherence and completion is likely to be associated with greater reduction in TB incidence and mortality. At a minimum, efforts to optimize uptake and adherence to ART and TPT should be prioritized among national ART programs in high-burden, resource-limited settings.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We are grateful to all the study participants and study team members of the AIDS Clinical Trials Group (ACTG) A5274 REMEMBER trial team. 

Disclaimer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no influence on the study design or analysis of the data.

Financial support. This work was funded by the US National Institutes of Health, National Institute of Allergy and Infectious Diseases through the AIDS Clinical Trials Group (Grants AI68636, AI069450, and UM1 AI068634) and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases (Grant UM1AI069465; to A. G.). S. K. was funded by the National Institutes of Health (Grant T32 AI007291-27). Pharmaceutical support was provided by Gilead Sciences.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. World Health Organization. Global tuberculosis report 2020. Available at: http://library1.nida.ac.th/termpaper/idi/2554/19755.pdf. Accessed 20 May 2022.
2. Gupta RK, Lusca SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015; 29:1987. doi:10.1097/QAD. 0000000000000882
3. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011; 6:e28691. doi:10.1371/journal.pone.0028691
4. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and inhospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc 2016; 19:20714. doi:10.7448/IAS.19.1.20714
5. Braithwaite P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817–24. doi:10.1016/S0140-6736(06)68337-2
6. Boule A, Schomaker M, May MT, et al. Mortality in patients with HIV infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med 2014; 11:e1001718. doi:10.1371/journal.pmed.1001718
7. Suthar AB, Lawn SD, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9:e1001270. doi:10.1371/journal.pmed.1001270
8. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012; 7:e34156. doi:10.1371/journal.pone.0034156
9. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy for the prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. J Int AIDS Soc 2016; 19:20714. doi:10.1016/S1021-3909(16)30513-4
10. The ItDeA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis 2018; 66:893–903. doi:10.1093/cid/cix915
11. Siedner MJ, Ng CK, Bassetti I V, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2003–2013: a meta-analysis. Clin Infect Dis 2015; 60:1120–7. doi:10.1093/cid/ciu1137
12. Ayele HT, van Mourik MSM, Debray TPA, Bonten MJM. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. PLoS One 2015; 10:e0142290. doi:10.1371/journal.pone.0142290
13. Tempemico ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808–22. doi:10.1056/ NEJMoa1507198
14. Akolo C, Adetiba I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 2010:CD000171. doi:10.1002/14651858.CD000171.pub2

15. Ross JM, Badje A, Rangaka MX, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021; 8:e8–15. doi:10.1016/S2352-3318(20)30299-X

16. World Health Organization. Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. Available at: https://apps.who.int/iris/handle/10665/260233. Accessed 20 May 2022.

17. Gupta S, Granich R, Lepere P, Hersh B, Gouws E, Samb B. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis 2014; 18:1149–58. doi:10.5588/ijtl.13.0889

18. Kaguije M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health 2019; 19:1–4. doi:10.1186/s12888-019-7652-x

19. Roscoe C, Lockhart C, de Klerk M, et al. Evaluation of the uptake of tuberculosis preventive therapy for people living with HIV in Namibia: a multiple methods analysis. BMC Public Health 2020; 20:1–12. doi:10.1186/s12889-020-09902-z

20. Nyathi S, Dlodlo RA, Satyanarayana S, et al. Isoniazid preventive therapy: uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One 2019; 14:e0223076. doi:10.1371/journal.pone.0223076

21. Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016; 387:1198–209. doi:10.1016/S0140-6736(16)00546-8

22. Matoga MM, Bisson GP, Gupta A, et al. Urine lipoarabinomannan testing in adults with advanced human immunodeficiency virus in a trial of empirical tuberculosis therapy. Clin Infect Dis 2021; 73:e870–7. doi:10.1093/cid/ciab179

23. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ACTG Adherence Self Report. Available at: https://www.frontierscience.org/apps/clima/apps/common/QOLAdherenceForms/resources/acct/forms/english/qol757.pdf. Accessed 21 September 2021.

24. Chaisson RE. Empirical antituberculosis therapy in advanced HIV disease—too much, too late. N Engl J Med 2011; 377:1588–98. doi:10.1056/NEJMoa1005136

25. Marthinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in HIV-infected patients. N Engl J Med 2011; 365:11–20. doi:10.1056/NEJMoa1005136

26. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215–22. doi:10.1097/00002030-20010216-00011

27. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Heal 2017; 5:e1080–9. doi:10.1016/S2214-109X(17)30372-8

28. Ousley J, Soe KP, Kyaw NTT, et al. IPT during HIV treatment in Myanmar: high rates of coverage, completion and drug adherence. Public Heal Action 2018; 8:20–4. doi:10.5588/phb.17.0087

29. Duroviv B, Cavalcanste SC, Saraceni V, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015; 60:639–45. doi:10.1093/cid/ciu849

30. Shayo GA, Moshiro C, Aboud S, Bakari M, Mugusi FM. Acceptability and adherence to isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis 2015; 15:1–8. doi:10.1186/s12879-015-1085-7

31. Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis 2014; 14:1–10. doi:10.1186/1471-2334-14-281

32. Holman SB, Atte S, Saharabudhe T, et al. Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study. JIMR Form Res 2019; 1:e13411. doi:10.2196/jmir.13411

33. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive therapy for people living with HIV in Namibia: a multiple methods study. Int J Tuberc Lung Dis 2014; 18:1149–58. doi:10.5588/ijtld.13.0889

34. Sensailre S, Nikol EKK, Nabwte J, et al. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. AIDS Res Ther 2020; 17:1–8. doi:10.1186/s12981-020-00285-0

35. World Health Organization. Global tuberculosis report 2015. Available at: https://apps.who.int/iris/handle/10665/191102. Accessed 15 May 2022.

36. Adams LV, Talbot EA, O dado K, Blunt H, Steingart KR. Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. BMC Infect Dis 2014; 14:1–10. doi:10.1186/1471-2334-14-281

37. Holman SB, Atte S, Saharabudhe T, et al. Use of smartphone-based video directly observed therapy (vDOT) in tuberculosis care: single-arm, prospective feasibility study. JIMR Form Res 2019; 1:e13411. doi:10.2196/jmir.13411

38. Sekandi JN, Bureggeya E, Zalwango S, et al. Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. ERJ Open Res 2020; 6:00175-02019. doi:10.1183/23120541.00175-2019

39. Harrtes AD, Kumar A, Satyanarayana S, et al. The growing importance of tuberculosis preventive therapy and how research and innovation can enhance its implementation on the ground. Trop Med Infect Dis 2020; 5:61. doi:10.3390/tropicalmed5020061